ArticleCureus2025
Robotic Excision of an Incidental Urachal Mucinous Cystadenocarcinoma in a Patient With Concomitant Endometrial Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urachal cystadenocarcinoma (UC) is a rare but highly aggressive subtype of bladder cancer. While most localized cases of UC are asymptomatic, occasionally, patients present with nonspecific lower urinary tract symptoms. Unfortunately, most cases are not detected until advanced disease is present. The presence of local nodal or distant metastasis is particularly important for prognosis, drastically reducing five-year overall survival rates. The gold standard for localized UC is wide surgical excision, with no established role of chemotherapy. On the contrary, endometrial carcinoma (EC) is the most common gynecologic malignancy. As such, staging, prognosis, and treatment guidelines of endometrial carcinoma are well-established. The gold standard treatment for localized endometrial carcinoma includes total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) and lymph node dissection (LND). Concurrent cases of urachal cystadenocarcinoma and endometrial carcinoma are exceedingly rare. To the authors' knowledge, there have been no known reports of these co-occurring malignancies thus far in the literature. We present the case of a 66-year-old patient with nonspecific lower urinary symptoms and incidentally discovered UC in the setting of concurrent endometrial carcinoma. The patient underwent robotic excision of the urachal cystadenocarcinoma and TAH-BSO, followed by adjuvant chemotherapy and vaginal brachytherapy. Surveillance imaging at 16 weeks after surgery showed no evidence of disease recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.